A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Status:
Completed

Trial end date:
2016-08-12

Target enrollment:

Participant gender:

An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068

Phase 1

Bristol-Myers Squibb
ViiV Healthcare

Covance

Fostemsavir